Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-3035
Hofmann-Lehmann, R; Tandon, R; Boretti, F S; Meli, M L; Willi, B; Cattori, V; Gomes-Keller, M A; Ossent, P; Golder, M C; Flynn, J; Lutz, H (2006). Reassessment of feline leukaemia virus (FeLV) vaccines with novel sensitive molecular assays. Vaccine, 24(8):1087-1094.
|PDF - Registered users only|
We previously described antigen negative, provirus positive cats. Subsequently, we hypothesized that efficacious FeLV vaccines cannot prevent minimal viral replication. Thus, we vaccinated cats with either a canarypox-vectored live or a killed virus vaccine and analyzed the challenge outcome with quantitative PCR and a newly established real-time RT-PCR. When judged by conventional parameters (antigenaemia, virus isolation), most of the vaccinated cats were, as expected, protected from persistent viraemia. However, all cats were found to be plasma viral RNA positive. The loads were significantly associated with the infection outcome. Thus, commonly used FeLV vaccines understood to be successful model antiretroviral vaccines protecting against FeLV-related diseases do not confer sterilizing immunity.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||05 Vetsuisse Faculty > Veterinary Clinic > Department of Farm Animals > Clinical Laboratory|
05 Vetsuisse Faculty > Institute of Veterinary Pathology
|DDC:||570 Life sciences; biology|
|Deposited On:||19 Aug 2008 10:58|
|Last Modified:||28 Nov 2013 02:02|
|Citations:||Web of Science®. Times cited: 32|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page